Independent Financial Group LLC Makes New $321,000 Investment in Illumina, Inc. $ILMN

Independent Financial Group LLC purchased a new stake in Illumina, Inc. (NASDAQ:ILMN) in the 1st quarter, Holdings Channel reports. The firm purchased 2,605 shares of the life sciences company’s stock, valued at approximately $321,000.

Other large investors have also modified their holdings of the company. Impact Partnership Wealth LLC grew its stake in shares of Illumina by 235.8% during the 1st quarter. Impact Partnership Wealth LLC now owns 11,080 shares of the life sciences company’s stock valued at $1,366,000 after buying an additional 7,780 shares during the period. SG Americas Securities LLC raised its position in shares of Illumina by 8.0% in the 1st quarter. SG Americas Securities LLC now owns 86,318 shares of the life sciences company’s stock worth $10,640,000 after buying an additional 6,425 shares during the period. Louisiana State Employees Retirement System acquired a new position in Illumina in the first quarter valued at $5,460,000. VIRGINIA RETIREMENT SYSTEMS ET Al boosted its holdings in Illumina by 27.4% in the fourth quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 348,011 shares of the life sciences company’s stock valued at $45,645,000 after acquiring an additional 74,900 shares during the last quarter. Finally, New York State Teachers Retirement System grew its position in Illumina by 2.7% during the fourth quarter. New York State Teachers Retirement System now owns 149,638 shares of the life sciences company’s stock valued at $19,627,000 after acquiring an additional 4,002 shares during the period. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the company. Royal Bank Of Canada assumed coverage on Illumina in a research note on Thursday, May 14th. They set an “outperform” rating and a $170.00 price target for the company. Leerink Partners boosted their target price on Illumina from $175.00 to $210.00 and gave the stock an “outperform” rating in a report on Friday, July 17th. Daiwa Securities Group raised shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 target price for the company in a research report on Thursday, May 14th. Guggenheim raised their price target on shares of Illumina from $180.00 to $200.00 and gave the company a “buy” rating in a report on Monday, June 29th. Finally, JPMorgan Chase & Co. raised shares of Illumina from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $125.00 to $185.00 in a research report on Wednesday, June 10th. Nine investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Illumina presently has an average rating of “Hold” and an average price target of $156.88.

Insider Activity

In other news, insider Scott M. Davies sold 615 shares of the company’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $180.00, for a total value of $110,700.00. Following the completion of the transaction, the insider directly owned 20,953 shares in the company, valued at approximately $3,771,540. This represents a 2.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Patricia Leckman sold 783 shares of the firm’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $162.59, for a total transaction of $127,307.97. Following the sale, the senior vice president directly owned 21,259 shares of the company’s stock, valued at approximately $3,456,500.81. The trade was a 3.55% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,003,769 shares of company stock worth $155,710,908 over the last three months. Insiders own 2.90% of the company’s stock.

Illumina Trading Down 1.4%

Shares of ILMN opened at $194.09 on Friday. Illumina, Inc. has a 12 month low of $88.00 and a 12 month high of $199.14. The stock’s 50-day moving average is $171.24 and its two-hundred day moving average is $145.40. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.75 and a quick ratio of 1.36. The stock has a market cap of $29.37 billion, a PE ratio of 35.29, a P/E/G ratio of 2.87 and a beta of 1.47.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.05 by $0.10. The business had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The company’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same quarter last year, the firm earned $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Equities analysts forecast that Illumina, Inc. will post 5.22 earnings per share for the current fiscal year.

Trending Headlines about Illumina

Here are the key news stories impacting Illumina this week:

• Neutral Sentiment: Illumina was highlighted in a batch of valuation and relative-performance articles comparing it with peers such as Exelixis and Celldex Therapeutics, which may be keeping attention on whether ILMN looks cheap or expensive versus other healthcare names. EXEL vs. ILMN: Which Stock Is the Better Value Option?
• Neutral Sentiment: Analyst sentiment remained middling, with Illumina reported as having an average “Hold” recommendation, suggesting Wall Street is not seeing an immediate reason to aggressively buy or sell the shares. Illumina, Inc. (NASDAQ:ILMN) Given Average Recommendation of “Hold” by Analysts
• Neutral Sentiment: Coverage around Illumina’s role in the Billion Cell Atlas alliance and broader genomics/CRISPR collaboration was noted in commentary on AstraZeneca, but this appears more like a long-term strategic backdrop than a near-term stock mover. AstraZeneca (LSE:AZN) And The Valuation Case Behind Its Drug Pipeline Narrative
• Neutral Sentiment: Short-interest data showed no meaningful change in reported shares outstanding for short positions, so there is no clear evidence here of a new bearish squeeze or panic selling signal.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.